Precision immunology: The promise of immunotherapy for the treatment of cancer

Journal of Clinical Oncology

Volumn 33, Issue 12, 2015, Pages 1315-1317

  Kaufman, Howard L ^a  

^a RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; CANCER VACCINE; CYCLOPHOSPHAMIDE; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN;

ADAPTIVE IMMUNITY; ANTIGEN PRESENTING CELL; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER REGRESSION; CYTOKINE PRODUCTION; DENDRITIC CELL; EDITORIAL; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOSURVEILLANCE; INNATE IMMUNITY; NONHUMAN; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TUMOR MICROENVIRONMENT; BIOSYNTHESIS; CARCINOMA, PANCREATIC DUCTAL; FEMALE; LISTERIA MONOCYTOGENES; MALE; METABOLISM; PANCREATIC NEOPLASMS;

CANCER VACCINES; CARCINOMA, PANCREATIC DUCTAL; CYCLOPHOSPHAMIDE; FEMALE; GPI-LINKED PROTEINS; HUMANS; LISTERIA MONOCYTOGENES; MALE; PANCREATIC NEOPLASMS;

EID: 84929403592     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.59.6023     Document Type: Editorial

References (16)

1. Raphael BJ, Dobson JR, Oesper L, et al: Identifying driver mutations in sequenced cancer genomes: Computational approaches to enable precision medicine. Genome Med 6:5, 2014
2. Sun C, Wang L, Huang S, et al: Reversible and adaptive resistance to BRAF9(V600E) inhibition in melanoma. Nature 508:118-122, 2014
3. Topalian SL, Weiner GJ, Pardoll DM: Cancer immunotherapy comes of age. J Clin Oncol 29:4828-4836, 2011
4. Chen DS, Mellman I: Oncology meets immunology: The cancer-immunity cycle. Immunity 39:1-10, 2013
5. Boone BA, Lotze MT: Targeting damage-associated molecular pattern molecules (DAMPs) and DAMP receptors in melanoma. Methods Mol Biol 1102:537-552, 2014
6. Spel L, Boelens JJ, Nierkens S, et al: Antitumor immune responses mediated by dendritic cells: How signals derived from dying cancer cells drive antigen cross-presentation. Oncoimmunology 2:e26403, 2013
7. Galon J, Angell HK, Bedognetti D, et al: The continuum of cancer immunosurveillance: Prognostic, predictive, and mechanistic signatures. Immunity 39:11-26, 2013
8. Butt AQ, Mills KH: Immunosuppressive networks and checkpoints controlling antitumor immunity and their blockade in the development of cancer immunotherapeutics and vaccines. Oncogene 33:4623-4631, 2014
9. Schreiber RD, Old LJ, Smyth MJ: Cancer immunoediting: Integrating immunity's roles in cancer suppression and promotion. Science 331:1565-1570, 2011
10. Vessely MD, Kershaw MH, Schreiber RD, et al: Natural innate and adaptive immunity to cancer. Annu Rev Immunol 29:235-271, 2011
11. Sauter B, Albert ML, Francisco L, et al: Consequences of cell death: Exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. J Exp Med 191: 423-434, 2000
12. Le DT, Wang-Gillam A, Picozzi V, et al: Safety and survival with GVAX pancreas prime and Listeria monocytogenes- expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer. J Clin Oncol 33:1325-1333, 2015
13. Hoos A, Eggermont AM, Janetzki S, et al: Improved endpoints for cancer immunotherapy trials. J Natl Cancer Inst 102:1388-1397, 2010
14. Hodi FS, Lee S, McDermott DF, et al: Ipilimumab plus sargramostim vs. ipilimumab alone for treatment of metastatic melanoma: A randomized clinical trial. JAMA 312:1744-1753, 2014
15. Fox BA, Schendel DJ, Butterfield LH, et al: Defining the critical hurdles in cancer immunotherapy. J Transl Med 9:214, 2011
16. Wolchok JD, Kluger H, Callahan MK, et al: Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 369:122-133, 2013